Glympse Bio
develops activity-based nanosensors whose protease-cleavable substrates release reporter fragments detectable in urine, with the underlying fluorogenic-substrate and protease-detection chemistry documented in peer-reviewed journals and multiple patent filings.
- Country
- United States
Growth
Activity-based nanosensors
Coverage
| CN | EU | US | |
|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ |
Regulatorsfdaema
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Synthetic biomarkers | diagnostics-medtech | High | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.